遲發性運動障礙治療市場規模、佔有率和成長分析（按治療方法、藥物、給藥途徑、最終用戶、分銷管道和地區分類）－2026-2033年產業預測

全球遲發性運動障礙治療市場規模預計在 2024 年達到 38.8 億美元，從 2025 年的 41.8 億美元成長到 2033 年的 76.3 億美元，在預測期（2026-2033 年）內複合年成長率為 7.8%。

受思覺失調症和躁鬱症等精神疾病盛行率上升的推動，全球遲發性運動障礙治療市場預計將持續成長。這些疾病通常需要長期抗精神病藥物治療，並可能導致遲發性運動障礙。 VMAT2抑制劑療法的進展以及監管機構對加速核准的支持進一步提升了市場潛力。新興國家醫療基礎設施的擴建改善了神經精神疾病患者的就醫途徑，而人們對遲發性運動障礙的認知不斷提高，也推動了相關治療的普及。然而，治療成本上升、現有療法的潛在副作用、發展中地區認知度不足以及患者群體較小導致研發投入有限等挑戰，可能會在短期內阻礙市場擴張。

推動全球遲發性運動障礙治療市場發展的因素

全球遲發性運動障礙治療市場主要受監管機構積極措施的推動，尤其是那些旨在加速新型治療方法核准流程、以滿足該疾病未滿足需求的措施。這些加速核准的途徑，包括簡審類和優先審評，激勵製藥公司推動創新治療方法的研發。因此，這種監管支持不僅提高了有前景的候選藥物快速進入市場的機會，也促進了這一重要醫療領域的投資和創新，從而對全球遲發性運動障礙治療市場的整體前景產生了積極影響。

全球遲發性運動障礙治療市場面臨的限制因素

全球遲發性運動障礙治療市場面臨嚴峻挑戰，主要原因是VMAT2抑制劑（常用的遲發性運動障礙治療藥物）的副作用。患者常出現疲勞、憂鬱和嗜睡等症狀，嚴重影響治療順從性和整體生活品質。這些不良反應可能導致部分患者選擇完全停止治療。此外，由於擔心這些藥物的長期安全性，醫療機構可能不願意開立此類藥物。因此，這些因素共同導致遲發性運動障礙有效治療方法的推廣應用緩慢。

遲發性運動障礙治療市場的全球趨勢

全球遲發性運動障礙治療市場正經歷顯著的成長趨勢，這主要得益於VMAT2抑制劑療法的進步。Valbenazine和Tetrabenazine等藥物的問世改變了治療模式，它們能夠更有效標靶治療緩解遲發性運動障礙的症狀，並顯著提高療效和安全性。此外，諸如Ingleza Sprinkle等創新劑型滿足了患者的需求，尤其是那些吞嚥困難的患者，從而有助於提高治療依從性和整體治療效果。這種以患者為中心的先進治療方法研發模式，使VMAT2抑制劑成為市場基石，並預示著未來將出現更多針對這種棘手疾病的高效且易於獲得的治療方案。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究

全球遲發性運動障礙治療市場規模（依療法和複合年成長率分類）（2026-2033 年）

• 藥物治療
• 手術治療

全球遲發性運動障礙治療市場規模（依藥物類別分類）及複合年成長率（2026-2033 年）

• 抗精神病藥物
• VMAT2抑制劑
• 肉毒桿菌毒素
• 自然療法
• 多巴胺耗竭藥物
• 其他

全球遲發性運動障礙治療市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服
• 注射

全球遲發性運動障礙治療市場規模（以最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 居家醫療
• 專科診所
• 其他

全球遲發性運動障礙治療市場規模（依通路分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 其他

全球遲發性運動障礙治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Neurocrine Biosciences, Inc.（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• H. Lundbeck A/S（Denmark）
• AbbVie Inc.（US）
• Otsuka Holdings Co., Ltd.（Japan）
• Astellas Pharma Inc.（Japan）
• Bausch Health Companies Inc.（Canada）
• Sumitomo Pharma America, Inc（US）
• Reviva Pharmaceuticals Holdings, Inc.（US）
• Acadia Pharmaceuticals Inc.（US）
• VANDA PHARMACEUTICALS（US）
• Eisai Co., Ltd.（Japan）
• Zydus Group（India）
• Lilly（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Pfizer Inc.（US）
• Bristol-Myers Squibb Company（US）
• Mallinckrodt（US）

結論與建議

Global Tardive Dyskinesia Treatment Market size was valued at USD 3.88 Billion in 2024 and is poised to grow from USD 4.18 Billion in 2025 to USD 7.63 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The global tardive dyskinesia treatment market is poised for growth driven by the rising prevalence of psychiatric disorders like schizophrenia and bipolar disorder, which often necessitate long-term antipsychotic treatment, leading to tardive dyskinesia. Advances in VMAT2 Inhibitor therapies and regulatory support for accelerated approvals further enhance market potential. Increased healthcare infrastructure in emerging economies is facilitating better access to neurological and psychiatric care, while growing awareness of tardive dyskinesia is promoting treatment adoption. However, challenges such as high treatment costs, potential adverse side effects of existing therapies, low awareness in developing regions, and limited research and development investment due to a small patient population may hinder market expansion in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tardive Dyskinesia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tardive Dyskinesia Treatment Market Segments Analysis

Global Tardive Dyskinesia Treatment Market is segmented by Treatment, Drugs, Route of administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Medication and Surgery. Based on Drugs, the market is segmented into Antipsychotics, VMAT2 Inhibitors, Botulinum Toxin, Natural Remedies, Dopamine-Depleting Medications and Others. Based on Route of administration, the market is segmented into Oral and Injectable. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is significantly driven by the proactive measures taken by regulatory authorities, particularly in facilitating faster approval processes for new therapies aimed at addressing the unmet medical needs associated with this condition. These expedited pathways, which include fast-track designations and priority reviews, encourage pharmaceutical companies to pursue the development of innovative treatments. As a result, this regulatory support not only enhances the likelihood of rapid market entry for promising drug candidates but also positively influences the overall outlook for the global tardive dyskinesia treatment market by stimulating investment and innovation in this critical area of healthcare.

Restraints in the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market faces notable challenges due to the side effects associated with VMAT2 inhibitors, which are commonly used to manage this condition. Patients often experience fatigue, depression, and somnolence, significantly affecting their adherence to treatment regimens and overall quality of life. These adverse effects can lead to some patients opting to discontinue their therapy altogether. Furthermore, healthcare providers may exhibit reluctance in prescribing these medications due to concerns regarding their long-term safety profiles. Consequently, these factors collectively contribute to a slower adoption of effective treatment options for tardive dyskinesia.

Market Trends of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is witnessing a significant trend driven by advancements in VMAT2 inhibitor therapies. The emergence of medications like valbenazine and deutetrabenazine has transformed the treatment landscape, offering targeted relief from the symptoms of tardive dyskinesia with enhanced efficacy and safety. Innovative formulations, such as Ingrezza Sprinkle, further address patient needs, specifically those with swallowing difficulties, thereby improving treatment adherence and overall outcomes. This focus on developing sophisticated and patient-centric therapies positions VMAT2 inhibitors as a cornerstone of the market, suggesting a future trend towards more effective and accessible treatment options for this challenging condition.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Tardive Dyskinesia Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Medication
• Surgery

Global Tardive Dyskinesia Treatment Market Size by Drugs & CAGR (2026-2033)

• Market Overview
• Antipsychotics
• VMAT2 Inhibitors
• Botulinum Toxin
• Natural Remedies
• Dopamine-Depleting Medications
• Others

Global Tardive Dyskinesia Treatment Market Size by Route of administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Tardive Dyskinesia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Tardive Dyskinesia Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Tardive Dyskinesia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Neurocrine Biosciences, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma America, Inc (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reviva Pharmaceuticals Holdings, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VANDA PHARMACEUTICALS (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lilly (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations